2m 2m 2m 2m 2m 2m 2m
Akebia Therapeut (AKBA)
NASDAQ
$0.96+$0.03 (+2.84%)
Price as of Jun 03, 2026 6:59 PM EDT- $273.6MMarket Cap
- -72.62%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Akebia Therapeut (AKBA)
$0.96+$0.03 (+2.84%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 227.3M +41.92% | 160.2M -17.70% | 194.6M -33.46% | 292.5M +36.94% | |
Cost of Revenue | 39.5M -37.54% | 63.2M -14.80% | 74.1M -13.34% | 85.6M -44.22% | |
Gross Profit | 187.9M +93.67% | 97.0M -19.48% | 120.5M -41.78% | 206.9M +243.81% | |
Sales and Marketing Expense | 107.5M +0.88% | 106.5M +6.30% | 100.2M -27.68% | 138.6M -20.42% | |
Research and Development Expense | -62.4M +65.62% | -37.7M -40.31% | -63.1M -51.47% | -130.0M -12.08% | |
Depreciation and Amortization Expense | 0 -100.00% | 36.0M 0.00% | 36.0M -0.003% | 36.0M 0.00% | |
Total Operating Expenses | 173.2M +17.47% | 147.5M -11.55% | 166.7M -42.05% | 287.7M -11.61% | |
Operating Profit | 23.5M +146.56% | -50.5M +9.11% | -46.3M -42.74% | -80.8M -69.55% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -24.2M +32.96% | -18.2M +201.48% | -6.0M -61.55% | -15.7M -21.31% | |
Interest Income and Expense and Net | -24.2M +32.96% | -18.2M +201.48% | -6.0M -61.55% | -15.7M -21.31% | |
Total Nonoperating Income and Expense | 58,000 -38.30% | 94,000 -89.40% | 887,000 -71.81% | 3.1M +30.32% | |
Income before Taxes | -3.7M -94.64% | -69.4M +33.67% | -51.9M -44.89% | -94.2M -66.69% | |
Income Taxes | 1.6M N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -5.3M -92.30% | -69.4M +33.67% | -51.9M -44.89% | -94.2M -66.69% | |
Net Income from Continuing Operations Applicable to Common | -3.7M -94.64% | -69.4M +33.67% | -51.9M -44.89% | -94.2M -66.69% | |
Basic EPS and Net Income | -0.02 -93.94% | -0.33 +17.86% | -0.28 -46.15% | -0.52 -69.41% | |
Diluted EPS and Net Income | -0.02 -93.94% | -0.33 +17.86% | -0.28 -46.15% | -0.52 -69.41% | |
Basic Weighted Average Shares | 257.2M +21.91% | 210.9M +12.53% | 187.5M +2.56% | 182.8M +10.14% | |
Diluted Weighted Average Shares | 257.2M +21.91% | 210.9M +12.53% | 187.5M +2.56% | 182.8M +10.14% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 184.8M +256.36% | 51.9M +20.84% | 42.9M -52.55% | 90.5M -39.61% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 184.8M +256.36% | 51.9M +20.84% | 42.9M -52.55% | 90.5M -39.61% | |
Total Current Assets | 253.0M +122.22% | 113.8M -3.65% | 118.1M -36.20% | 185.2M -31.92% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | 9.3M +21.58% | |
Property and Plant and Equipment and Net | 1.2M -44.45% | 2.2M -39.38% | 3.6M -30.40% | 5.2M -22.80% | |
Total Long-Term Assets | 59.7M +59.67% | 37.4M +200.87% | 12.4M +131.25% | 5.4M -89.20% | |
Total Assets | 376.6M +70.65% | 220.7M -8.70% | 241.7M -32.12% | 356.1M -32.25% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | 0 -100.00% | 17.5M -45.31% | 32.0M -67.19% | |
Total Current Liabilities | 162.9M +101.37% | 80.9M -18.98% | 99.9M -22.90% | 129.5M -49.50% | |
Total Long-Term Debt | 48.3M +24.70% | 38.7M +125.18% | 17.2M -49.58% | 34.1M N/A | |
Total Long-Term Liabilities | 1.8M -61.61% | 4.7M -46.55% | 8.9M -43.47% | 15.7M -80.95% | |
Total Liabilities | 344.0M +27.46% | 269.9M -0.89% | 272.3M -22.39% | 350.8M -21.88% | |
Retained Earnings | -1.7B +0.32% | -1.7B +4.31% | -1.6B +3.33% | -1.6B +6.62% | |
Total Stockholders Equity | 32.6M +166.30% | -49.2M +60.82% | -30.6M -684.78% | 5.2M -93.16% | |
Total Shares Outstanding | 265.4M +18.05% | 224.8M +15.55% | 194.6M +5.67% | 184.1M +4.03% | |
Cash Flow | |||||
Cash from Operating Activities | 68.0M +267.22% | -40.7M +73.88% | -23.4M -68.03% | -73.2M -71.08% | |
Capital Expenditures | 291,000 +781.82% | 33,000 N/A | 0 -100.00% | 114,000 +93.22% | |
Cash from Investing Activities | -7.9M +23,918.18% | -33,000 N/A | 0 +100.00% | -114,000 -100.29% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 72.9M +46.84% | 49.7M +297.03% | -25.2M -272.67% | 14.6M -89.08% | |
Financials Ratio | |||||
Gross Margin | 82.64% +36.46% | 60.56% -2.17% | 61.90% -12.50% | 70.74% +151.05% | |
Operating Margin | 10.34% +132.81% | -31.51% +32.58% | -23.77% -13.94% | -27.62% -77.77% | |
Return on Assets | -1.79% -94.04% | -30.02% +72.81% | -17.37% -18.73% | -21.38% -55.80% | |
Return on Equity | 64.49% -62.94% | 174.03% -57.51% | 409.60% +277.54% | -230.70% +32.17% | |
Revenue Growth | 41.92% +336.89% | -17.70% -47.11% | -33.46% -190.56% | 36.94% +233.49% | |
Current Ratio | 1.55 +10.36% | 1.41 +18.92% | 1.18 -17.25% | 1.43 +34.80% | |
Cash Ratio | 1.13 +76.95% | 0.64 +49.16% | 0.43 -38.46% | 0.70 +19.59% | |
Debt-to-Equity Ratio | N/A N/A | -0.79 -30.63% | -1.13 -108.98% | 12.63 +890.31% | |
Debt-to-Assets Ratio | N/A N/A | 0.18 +22.16% | 0.14 -22.68% | 0.19 0.00% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow